Jack Choi, MD
Family Medicine · Burien, WANPI 1902840382
Payments from drug & device makers
Across 56 payments — averaging $41.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$184
- AstraZeneca$90
- Novo Nordisk$77
- Boehringer Ingelheim$54
- Sanofi-aventis U.S. LLC$49
- plus $105 from 6 others
What the payments were for
- Speaking & faculty fees$1,58268%
- Food & beverage$75132%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $1,774 |
| Amgen(2 entities) | 10 | $184 |
| AstraZeneca | 4 | $90 |
| Novo Nordisk | 4 | $77 |
| Boehringer Ingelheim | 2 | $54 |
| Sanofi-aventis U.S. LLC | 2 | $49 |
| Kowa Pharmaceuticals America, Inc. | 1 | $28 |
| Abbott | 1 | $23 |
| Lilly USA, LLC | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Novartis | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
How this compares
$2,333 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 77 | $112,814 |
| Tresiba Flextouch U-100Insulin Degludec | 78 | $56,463 |
| Spiriva HandihalerTiotropium Bromide | 48 | $45,571 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $32,527 |
| XareltoRivaroxaban | 18 | $25,648 |
| JanuviaSitagliptin Phosphate | 14 | $22,116 |
| Xtampza ErOxycodone Myristate | 12 | $16,586 |
| EliquisApixaban | 14 | $16,238 |
| Atrovent HfaIpratropium Bromide | 22 | $12,013 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 81 | $11,884 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $10,003 |
| Repatha SureclickEvolocumab | 18 | $9,942 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 282 | $8,682 |
| Nebivolol Hcl | 134 | $8,565 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,070 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $77 | $112,81477 claims |
| Boehringer IngelheimCombivent Respimat | $54 | $10,00318 claims |
| AstraZenecaSymbicort | $90 | $3,61715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Burien
- Daniel RivasBurien$50K
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
- Steven KasterWenatchee$4M
- Angela EakinSpokane$3M
- Jonathan StabenCheney$2.5M
- Emily ZaragozaSeattle$1.9M
- Brad FrandsenPort Orchard$1.7M
- Kevin HatfieldSeattle$527K
- Steven SmithAuburn$438K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.